GBIOLOGICS(‘GBIO’) is a Korean biotech company developing therapeutics for autoimmune diseases (Rheumatoid Arthritis & Systemic Lupus Erythematosus) with a patented recombinant protein called “stable Galectin-9 (sGal-9)” as a platform technology. GBIO was founded in 2018 by David Song as a CEO, who is a veterinarian studied at Seoul National University. He worked at Green Cross and LG Chem as team head of biopharmaceutical product development. Andrew Han as a COO studied at Northwestern University and worked at TS corp. as director of biopharmaceutical division. Hyosil Lee as a CTO studied at Ohio University and worked at Mogam Inst. as director of biopharmaceutical division. David and his team are experts in developing biopharmaceutical products with more than 30 years of experience in the field, successfully conducted over 30 projects with more than 20 IND applications and approvals, as well as over 10 NDA applications and approvals, to date.